Gamma Medica-Ideas adds Asian distributors, names director

AuntMinnie.com staff writers

May 15, 2006

Molecular imaging systems developer Gamma Medica-Ideas has selected distributors to sell and service its Flex preclinical imaging system in Japan and South Korea.

The distribution agreements give Tokyo-based SII NanoTechnology exclusive rights to distribute Gamma Medica-Ideas' Flex preclinical imaging system in Japan, while Seoul-based Taihan Metra wins exclusive rights to distribute the technology in South Korea, according to the Northridge, CA-based firm.

In related news, Gamma Medica-Ideas reported that Koji Iwata, Ph.D., has been appointed director of Asian operations. Iwata has been with the firm since 2002, and most recently was its manager of applications and support.

By AuntMinnie.com staff writers
May 16, 2006

Related Reading

Gamma Medica-Ideas posts strong December, January 20, 2006

Gamma Medica-Ideas upgrades X-SPECT, December 1, 2005

Gamma Medica-Ideas nets Italy sales, November 29, 2005

Gamma Medica-Ideas opens Oslo office, November 11, 2005

Road to RSNA, Gamma Medica-Ideas, November 3, 2005

Copyright © 2006 AuntMinnie.com

PET/CT can rule out CAV in heart transplant patients

January 17, 2025

Fapi Pet Gastric Cancer Thumbnail

FAPI-PET shows promise for imaging gastric cancers

January 16, 2025

New! Imaging Life Issue 20 now available

New! Imaging Life Issue 20 now available

January 1, 2025

Micro-PET/CT images of rats. (a) At 24 hours in the control group, F-18 FDG uptake in rats brain tissue was normal, and the PET/CT images were red and white; (b) At 7 days in the control group, F-18 FDG uptake in rats brain tissue were normal, and the PET/CT images were red and white; (c) At 24 hours after TMT exposure, F-18 FDG uptake in rats brain tissue were in a low state, and the PET/CT images were orange and yellow. (d) 7 days after TMT exposure, F-18 FDG uptake in rats brain tissue further decreased, and the PET/CT images appeared yellow and light yellow. There was no significant difference in the uptake of muscle tissue between the model group and the control group, and the PET/CT image was blue. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of Scientific Reports.

Animal study shows PET/CT can detect brain damage from TMT poisoning

January 9, 2025

PET/CT can rule out CAV in heart transplant patients

Cardiac PET/CT scans can effectively rule out moderate to severe cardiac allograft vasculopathy (CAV) in heart transplant patients.

January 17, 2025

FAPI-PET shows promise for imaging gastric cancers

Gallium-68 fibroblast activation protein inhibitor (FAPI) PET/CT is a promising new method for imaging gastric cancer.

January 16, 2025

Fapi Pet Gastric Cancer Thumbnail

PET tracks long-term changes in patients with dementia

PET imaging can assess brain metabolism changes over time in individuals with prodromal dementia with Lewy bodies (DLB) and probable DLB.

January 13, 2025

Animal study shows PET/CT can detect brain damage from TMT poisoning

A feasibility study in rats suggests that PET/CT can detect brain damage caused by trimethyltin chloride (TMT), a hazardous compound widely used in plastics production.

January 9, 2025

Micro-PET/CT images of rats. (a) At 24 hours in the control group, F-18 FDG uptake in rats brain tissue was normal, and the PET/CT images were red and white; (b) At 7 days in the control group, F-18 FDG uptake in rats brain tissue were normal, and the PET/CT images were red and white; (c) At 24 hours after TMT exposure, F-18 FDG uptake in rats brain tissue were in a low state, and the PET/CT images were orange and yellow. (d) 7 days after TMT exposure, F-18 FDG uptake in rats brain tissue further decreased, and the PET/CT images appeared yellow and light yellow. There was no significant difference in the uptake of muscle tissue between the model group and the control group, and the PET/CT image was blue. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of Scientific Reports.

New criteria released for amyloid and tau PET imaging

New appropriate use criteria for amyloid and tau PET imaging of amyloid and tau pathology has been released.

January 8, 2025

PET scans can decrease unnecessary lymph node procedures

Negative prostate-specific antigen PET scans can be used to avoid unnecessary pelvic lymph node dissection in certain prostate cancer patients undergoing radical prostatectomies.

January 7, 2025

PSMA-PET imaging spiked after FDA approval

Rates of PET prostate cancer imaging increased rapidly after its approval by the U.S. Food and Drug Administration (FDA).

January 6, 2025

Prostate Imaging2

PSMA-PET/CT bests conventional imaging for prostate cancer diagnosis

By Kate Madden Yee

PSMA-PET/CT bests conventional imaging when it comes to identifying high-risk, nonmetastatic, hormone-sensitive prostate cancer, researchers say.

January 3, 2025

Prostate Cancer

Kidneys appear to tolerate Lu-177 treatments

Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.

December 19, 2024

African American men respond more favorably to Ra-223 therapy

African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.

December 17, 2024

Prostate Imaging

PET visualizes acute graft vs. host disease

F-18 fluorothymidine PET can identify early acute gastrointestinal graft versus host disease after patients undergo bone marrow transplants.

December 16, 2024

F-18 FLT-PET imaging of gastrointestinal GVHD. Examples of F-18 FLT uptake in a participant with no GVHD (left) and a participant with acute GVHD and uptake in the jejunum and ileum (right). Arrows denote increased uptake in the GI tract. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of RSNA.

Immuno-PET tracer shows promise in patients with liver cancer

A new PET radiotracer has the potential for visualizing responses in liver cancer patients undergoing immunotherapy.

December 12, 2024

PET/CT images of F-18 AlF-NOTA-BCP137 in patients with hepatocellular carcinoma (HCC) and immunofluorescence analysis of patient tissues. (A) F-18 AlF-NOTA-BCP137 PET/CT images before and after immunotherapy for patient 1 and patient 2. (B) F-18 AlF-NOTA-BCP137 PET/CT and MR images of patient 3 (left panels) after one cycle of immunotherapy. PET images showed higher uptake by tumor and spleen, and PET result was evaluated as positive; therefore, the patient was considered to be responder to treatment and underwent surgical resection. Representative images of hematoxylin and eosin (HE) staining and multiplex immunofluorescence of CD8 and CD137 (right panels) in HCC tumor and adjacent normal tissues of patient 3 after surgery. Nuclei were stained with 4′,6-diamidino-2-phenylindole. Primary tumors are indicated by white arrows, and increased thyroid uptake is indicated by red arrow in PET images. Image courtesy of the Journal of Nuclear Medicine.

Page 1 of 599